On the Significance of Antithrombin-III, α₂-Macroglobulin, α₂-Antiplasmin, Histidine-Rich Glycoprotein, and Protein C in Patients with Acute Myocardial Infarction and Deep Vein Thrombosis

Summary

In a longitudinal study the plasma levels of antithrombin-III, α₂-macroglobulin, α₂-antiplasmin, histidine-rich glycoprotein, and protein C were followed in two groups of patients with acute myocardial infarction (AMI), one with and one without deep vein thrombosis (DVT). None of the sequentially studied periods revealed significant differences between the two groups of patients. However, small but consistently higher levels of histidine-rich glycoprotein in patients with DVT suggested the existence among patients submitted for myocardial infarction of a subgroup with increased thrombophilic potential. It was concluded that the inhibitors studied are of little value as possible indicators of the presence of DVT at early stages of the disease when clinical signs are absent and when antithrombotic prophylaxis should preferably be initiated.

Keywords

Deep vein thrombosis - Antithrombin-III - α₂-macroglobulin - α₂-antiplasmin - Histidine-rich glycoprotein - Protein C

• References

• 1 Murray TS, Lorimer AR, Cox FC, Lawrie TDV. Leg-vein thrombosis following myocardial infarction. Lancet 1970; 2: 792-793
• 2 Jespersen J, Gram J, Christensen L, Astrup T. Detection of deep vein thrombosis following myocardial infarction by the technetium-99m-plasmin test. Nucl Med Common 1983; 4: 194-203
• 3 Astrup T. The biological significance of fibrinolysis. Lancet 1956; 2: 565-568
• 4 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thrombos Diathes Haemorrh 1965; 13: 516-530
• 5 Aoki N. Genetic abnormalities of the fibrinolytic system. Semin Thromb Haemostas 1984; 10: 42-50
• 6 Brommer EJP, Leuven JAG, Kluft C, Wijngaards G. Fibrinolytic inhibitor in type II hyperlipoproteinaemia. Lancet 1983; 2: 1066
• 7 Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-1373
• 8 Bertina RM, Broekmans AW, van der Linden IK, Mertens K. Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemostas 1982; 48: 01-05
• 9 Olsson CG, Albrechtsson U, Darte L, Persson RBR. ^99mTc-plasmin for rapid detection of deep vein thrombosis. Nucl Med Commun 1982; 3: 41-52
• 10 Jespersen J, Sidelmann J. Individual levels of plasma α₂-antiplasmin and α₂-macroglobulin during the normal menstrual cycle and in women on oral contraceptives low in oestrogen. Thromb Haemostas 1983; 50: 581-585
• 11 Jespersen J, Gram J, Bach E. A sequential study of plasma histidine-rich glycoprotein and plasminogen in patients with acute myocardial infarction and deep vein thrombosis. Thromb Haemostas 1984; 51: 99-102
• 12 Neumier D, Prellwitz W, Knedel M. Infarct size estimation from serial analysis of creatine kinase and isoenzyme activity. In: Creatine kinase isoenzymes. Pathophysiology and Clinical Application. Long H. (Ed). Springer Verlag; New York: 1981: 155-156
• 13 von Kaulla E, von Kaulla KN. Antithrombin III and Diseases. Am J Clin Pathol 1967; 48: 69-80
• 14 Hedner U, Nilsson IM. Antithrombin III in a clinical material. Thromb Res 1973; 3: 631-641
• 15 Lechner K, Thaler E, Niessner H, Nowotny CH, Partsch H. Antithrombin-III-Mangel und Thromboseneigung. Wien klin Wochenschr 1977; 89: 215-222
• 16 Stormorken H, Erikssen J. Plasma antithrombin III and factor VIII antigen in relation to angiographic findings, angina and blood groups in middle-aged men. Thromb Haemostas 1977; 38: 874-880
• 17 DeBoer AC, van Riel LAM, den Ottolander GJH. Measurement of antithrombin-III, α₂-macroglobulin and α₁-antitrypsin in patients with deep vein thrombosis and pulmonary embolism. Thromb Res 1979; 15: 17-25
• 18 Losito R, Gattiker H, Bilodeau G, Verville N, Longpré B. Levels of antithrombin III, α₂-macroglobulin and alpha 1-antitrypsin in acute ischaemic heart disease. J Lab Clin Med 1981; 97: 241-250
• 19 Baker IA, Eastham R, Elwood PC, Etherington M, O’Brien JR, Sweetnam PM. Haemostatic factors associated with ischaemic heart disease in men aged 45 to 64 years. The Speedwell study. Br Heart J 1982; 47: 490-494
• 20 Schöndorf TH, Oehler G. Antithrombin III-decrease after operations and myocardial infarction due to postaggressive syndromes. Thromb Haemostas. 1983 50. 50 (Abstr)
• 21 Nilsson IM, Krook H, Sternby N-H, Söderberg E, Söderström N. Severe thrombotic disease in a young man with bone marrow and skeletal changes and with a high content of an inhibitor in the fibrinolytic system. Acta med Scand 1961; 169: 323-337
• 22 Brakman P, Mohler ER, Astrup T. A group of patients with impaired plasma fibrinolytic system and selective inhibition of tissue activator-induced fibrinolysis. Scand J Haematol 1966; 3: 389-398
• 23 Lijnen HR, Hoylaerts M, Collen D. Isolation and characterization of a human plasma protein with affinity for lysine binding sites in plasminogen. J Biol Chem 1980; 255: 10214-10222
• 24 Gram J, Jespersen J, Astrup T. The diagnosis of deep vein thrombosis. Lancet 1984; II: 1399-1400
• 25 Jespersen J. A study of the antithrombotic potential in women on oral contraceptives low in oestrogen. In: Clinical Aspects of Fibrinolysis and Thrombolysis. Jespersen J, Kluft C, Korsgaard O. (Eds). Esbjerg; Denmark: South Jutland University Press: 1983: 399-420